• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number RLT281414
Medical Device Problem Code Patient-Device Incompatibility (2682)
Health Effect - Clinical Codes Aneurysm expansion (4597); Clinical Endoleak (4843)
Date of Event 04/10/2024
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
H6: code c19 - a review of the manufacturing records indicated the lot met all pre-release specifications.H6: code b20 -the device remains implanted and was therefore not available for engineering evaluation by gore.According to the gore® excluder® aaa endoprosthesis instructions for use (ifu), potential adverse events that may occur and/or require intervention include, but are not limited to aneurysm enlargement, endoleak and reoperation.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event or Problem Description
The following was reported to gore: on (b)(6) 2017, the patient underwent an endovascular procedure utilizing gore® excluder® aaa endoprosthesis (trunk ipsilateral leg c3 and three contralateral legs).On (b)(6) 2024, the field sales associate was notified by the nurse (rn) that the patient has a suspected type 2 endoleak.An angiogram will be done next week to try and determine what type of leak it is.On (b)(6) 2024, the patient underwent an angiogram to determine the type of endoleak, physician suspected it to be a type 1a or 2 endoleak but they were unable to confirm.There was also aneurysm growth of 7.9cm.During the same day, as they were unable to confirm either type 1a or 2 endoleak, physician did a reintervention by extending proximally from the trunk ipsilateral leg c3 with a gore® excluder®aaa endoprosthesis (aortic extender) which resolved the suspected type 1a endoleak.
 
Additional Manufacturer Narrative
Added g3/g4, h1/h2, h6.Imaging evaluation summary: the imaging evaluation performed by a clinical imaging specialist showed the following: images provided are cta dated (b)(6) 2024, prior to the re-intervention.Image set is incomplete and does not extend distal enough to review the entire aneurysm, aortic bifurcation, or iliac vessels.Images are arterial phase only.There appears to be wall apposition at the proximal end of the graft.There is a contrast-like density visible outside of the graft, however, contrast cannot be confirmed without a non-contrast or delay phase for comparison.Unable to confirm aneurysm growth with only one image set, and images are incomplete.Additional timepoints for comparison are not available for review.Max diameter visualized measures ~ 61 mm x 77 mm.According to the gore® excluder® aaa endoprosthesis instructions for use (ifu), potential adverse events that may occur and/or require intervention include, but are not limited to aneurysm enlargement, endoleak and reoperation.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® EXCLUDER® AAA ENDOPROSTHESIS
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL PHOENIX 2 B/P
32470 n. north valley parkway
phoenix AZ 85085
Manufacturer Contact
jaskaran parhar
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key19251822
Report Number3007284313-2024-03208
Device Sequence Number15102878
Product Code MIH
UDI-Device Identifier00733132622535
UDI-Public00733132622535
Combination Product (Y/N)N
Initial Reporter StateMS
Initial Reporter CountryUS
PMA/510(K) Number
P020004
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2017
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Company Representative
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 05/22/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date08/11/2019
Device Catalogue NumberRLT281414
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 04/10/2024
Supplement Date Received by Manufacturer05/22/2024
Initial Report FDA Received Date05/06/2024
Supplement Report FDA Received Date05/22/2024
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured08/11/2016
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Hospitalization; Other; Required Intervention;
Patient Age78 YR
Patient SexMale
-
-